http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104983729-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-353 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate | 2015-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104983729-B |
| titleOfInvention | Catechin compounds and gallic acid combination are preparing the new application in treating antihyperuricemic disease drug |
| abstract | The invention discloses nutgall catechin, catechin and gallate or nutgall catechin gallic acid ester and its pharmaceutically acceptable salt and gallic acid use in conjunction, the purposes for treating hyperuricemia.Catechin compounds of the present invention not only show stronger In-vitro Inhibitory Effect to xanthine oxidase, the serum uric acid level with hyperuricemia mouse is also can obviously reduce, the treatment of potential xanthine oxidase inhibitor and anti-trioxypurine drug for gout or gout complication caused by hyperuricemia and hyperuricemia is can be used as. |
| priorityDate | 2015-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 72.